153 related articles for article (PubMed ID: 21952919)
1. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas.
Giaisi M; Köhler R; Fulda S; Krammer PH; Li-Weber M
Int J Cancer; 2012 Aug; 131(4):1003-8. PubMed ID: 21952919
[TBL] [Abstract][Full Text] [Related]
2. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC
Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763
[TBL] [Abstract][Full Text] [Related]
4. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.
Luan Z; He Y; He F; Chen Z
Mol Med Rep; 2015 Jan; 11(1):203-11. PubMed ID: 25333816
[TBL] [Abstract][Full Text] [Related]
5. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia.
Loeder S; Zenz T; Schnaiter A; Mertens D; Winkler D; Döhner H; Debatin KM; Stilgenbauer S; Fulda S
Cancer Res; 2009 Dec; 69(23):8977-86. PubMed ID: 19920200
[TBL] [Abstract][Full Text] [Related]
6. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
7. 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation.
Han H; Shin SW; Seo CY; Kwon HC; Han JY; Kim IH; Kwak JY; Park JI
Apoptosis; 2007 Nov; 12(11):2101-14. PubMed ID: 17786557
[TBL] [Abstract][Full Text] [Related]
8. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
Venza I; Visalli M; Oteri R; Teti D; Venza M
Int Immunopharmacol; 2014 Aug; 21(2):439-46. PubMed ID: 24946096
[TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.
Huang Y; Yang X; Xu T; Kong Q; Zhang Y; Shen Y; Wei Y; Wang G; Chang KJ
Int J Oncol; 2016 Jul; 49(1):153-63. PubMed ID: 27210546
[TBL] [Abstract][Full Text] [Related]
10. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
[TBL] [Abstract][Full Text] [Related]
12. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression.
Bleumink M; Köhler R; Giaisi M; Proksch P; Krammer PH; Li-Weber M
Cell Death Differ; 2011 Feb; 18(2):362-70. PubMed ID: 20706274
[TBL] [Abstract][Full Text] [Related]
13. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.
Siegelin MD; Gaiser T; Siegelin Y
Neurochem Int; 2009 Nov; 55(6):423-30. PubMed ID: 19409438
[TBL] [Abstract][Full Text] [Related]
14. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
15. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
16. Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model.
Wu Y; Giaisi M; Köhler R; Chen WM; Krammer PH; Li-Weber M
Cancer Lett; 2017 Mar; 389():70-77. PubMed ID: 27998762
[TBL] [Abstract][Full Text] [Related]
17. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death.
Dutton A; O'Neil JD; Milner AE; Reynolds GM; Starczynski J; Crocker J; Young LS; Murray PG
Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6611-6. PubMed ID: 15096587
[TBL] [Abstract][Full Text] [Related]
18. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
[TBL] [Abstract][Full Text] [Related]
19. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.
Song JH; Tse MC; Bellail A; Phuphanich S; Khuri F; Kneteman NM; Hao C
Cancer Res; 2007 Jul; 67(14):6946-55. PubMed ID: 17638906
[TBL] [Abstract][Full Text] [Related]
20. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells.
Roa WH; Chen H; Fulton D; Gulavita S; Shaw A; Th'ng J; Farr-Jones M; Moore R; Petruk K
Clin Invest Med; 2003 Oct; 26(5):231-42. PubMed ID: 14596484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
